Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00788931
What this trial is testing

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerMetastatic Breast Cancer
Novartis Pharmaceuticals 15
Large-scale testing (Phase 3)Study completedNCT03084939
What this trial is testing

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 351
Large-scale testing (Phase 3)Study completedNCT01125566
What this trial is testing

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 508
Not applicableStudy completedNCT06525675
What this trial is testing

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more
MedSIR 419
Early research (Phase 1)Ended earlyNCT01805908
What this trial is testing

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Who this might be right for
Breast Cancer
Ontario Clinical Oncology Group (OCOG) 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618
What this trial is testing

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Not applicableEnded earlyNCT02611310
What this trial is testing

Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 15
Early research (Phase 1)Study completedNCT00650910
What this trial is testing

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 17
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Ended earlyNCT00759642
What this trial is testing

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 33
Not applicableApproved For MarketingNCT04220203
What this trial is testing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Study completedNCT01138046
What this trial is testing

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 12
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Not applicableStudy completedNCT04857619
What this trial is testing

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 763
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Not applicableActive Not RecruitingNCT04030507
What this trial is testing

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer+3 more
Brigham and Women's Hospital 214
Testing effectiveness (Phase 2)Study completedNCT01548677
What this trial is testing

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

Who this might be right for
Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastCirculating Tumor Cells
European Organisation for Research and Treatment of Cancer - EORTC 1,317
Next Page